论文部分内容阅读
目的:评价唑来膦酸与放疗联用治疗肺癌骨转移患者的临床疗效。方法:选取2012年3月—2014年12月间收治的肺癌骨转移患者80例作为研究对象,将其分为对照组和观察组,每组40例;对照组患者均给予唑来膦酸治疗,观察组患者在对照组的基础上给予放疗联用治疗,评价两组患者治疗后的临床疗效(疼痛缓解情况、生存质量改善情况等)和治疗期间药物不良反应的发生情况。结果:观察组患者治疗后的疼痛缓解率为90.00%显著高于对照组为72.50%(P<0.05);其生存质量改善率为87.50%显著高于对照组为62.50%(P<0.05);但观察组各项不良反应的发生率为97.50%显著高于对照组为15.00%(P>0.05)。结论:唑来膦酸与放疗联用治疗肺癌骨转移患者的临床疗效较好,疼痛缓解率较高,有利于患者生存质量的改善,是比较理想的治疗方法,但需对治疗中产生的不药物不良反应症状应采取积极地防治措施。
Objective: To evaluate the clinical efficacy of zoledronic acid combined with radiotherapy in the treatment of patients with bone metastasis of lung cancer. Methods: Eighty patients with bone metastasis of lung cancer who were treated between March 2012 and December 2014 were selected as study subjects, which were divided into control group and observation group, 40 cases in each group. Patients in the control group were treated with zoledronic acid The patients in the observation group were treated with radiotherapy on the basis of the control group, and the clinical efficacy (pain relief, quality of life improvement, etc.) and the incidence of adverse drug reactions during the treatment were evaluated. Results: The pain relief rate of observation group was 90.00%, which was significantly higher than that of control group (72.50%, P <0.05). The improvement rate of quality of life in observation group was 87.50%, which was significantly higher than that in control group (62.50%, P <0.05). However, the incidence of adverse reactions in the observation group was 97.50%, significantly higher than that of the control group (15.00%, P> 0.05). Conclusion: Zoledronic acid combined with radiotherapy for the treatment of patients with bone metastases of lung cancer has better clinical curative effect and higher pain relief rate, which is beneficial to the improvement of patients’ quality of life, which is an ideal treatment method. However, Adverse drug reactions symptoms should take active control measures.